Krystal Biotech, Inc. financial data

Symbol
KRYS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.36K % -2.57%
Quick Ratio 19.7 %
Debt-to-equity 6.52 % -0.76%
Return On Equity 13.4 %
Return On Assets 12.5 %
Operating Margin -12.6 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.7M shares +2.63%
Common Stock, Shares, Outstanding 28.7M shares +2.62%
Entity Public Float 2.8B USD +100%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 28.6M shares +7.28%
Weighted Average Number of Shares Outstanding, Diluted 29.6M shares +11.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 166M USD
Research and Development Expense 48.5M USD +3.96%
General and Administrative Expense 93.9M USD +67.1%
Operating Income (Loss) -21M USD +86.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 16M USD
Income Tax Expense (Benefit) 477K USD
Net Income (Loss) Attributable to Parent 106M USD
Earnings Per Share, Basic 3.98 USD/shares
Earnings Per Share, Diluted 3.96 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 346M USD +25.3%
Cash, Cash Equivalents, and Short-term Investments 560M USD +17.2%
Accounts Receivable, after Allowance for Credit Loss, Current 103M USD
Inventory, Net 12.2M USD
Assets, Current 683M USD +41.1%
Property, Plant and Equipment, Net 159M USD -3.01%
Operating Lease, Right-of-Use Asset 6.66M USD -12.3%
Other Assets, Noncurrent 126K USD -55.8%
Assets 918M USD +34.2%
Accounts Payable, Current 5.43M USD +22%
Liabilities, Current 71.9M USD +201%
Operating Lease, Liability, Noncurrent 6.33M USD -9.81%
Other Liabilities, Noncurrent 588K USD
Liabilities 78.8M USD +155%
Accumulated Other Comprehensive Income (Loss), Net of Tax -634K USD -169%
Retained Earnings (Accumulated Deficit) -253M USD +29.5%
Stockholders' Equity Attributable to Parent 839M USD +28.4%
Liabilities and Equity 918M USD +34.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 15.9M USD
Net Cash Provided by (Used in) Financing Activities 10.6M USD +618%
Net Cash Provided by (Used in) Investing Activities -26M USD -829%
Common Stock, Shares Authorized 80M shares 0%
Common Stock, Shares, Issued 28.7M shares +2.62%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 678K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 346M USD +25.3%
Deferred Tax Assets, Valuation Allowance 77M USD -6.69%
Deferred Tax Assets, Gross 91.6M USD +6.74%
Operating Lease, Liability 7.69M USD -10%
Depreciation 5.94M USD +49.3%
Payments to Acquire Property, Plant, and Equipment 1.26M USD -76.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 106M USD
Lessee, Operating Lease, Liability, to be Paid 15.4M USD -9.4%
Property, Plant and Equipment, Gross 176M USD +1.94%
Operating Lease, Liability, Current 1.36M USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.28M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.28M USD -17%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.7M USD -8.77%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.3M USD +1.8%
Deferred Tax Assets, Operating Loss Carryforwards 40M USD -24%
Preferred Stock, Shares Issued 2.06M shares 0%
Preferred Stock, Shares Authorized 20M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.33M USD +1.92%
Additional Paid in Capital 1.09B USD +7.92%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 14.6M USD +342%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%